NCT07838155
A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease
At risk: Primary completion moved at least 32 days later.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below.
- Minor Primary and study completion pushed from Jul 2030 to Sep 2030
- Trial sites expanded: 9 → 12 locations
- Start date pushed from Oct 2026 to Nov 2026
- Study First Submitted
- Minor: routine updates
Endpoints
Primary
Number of Participants with Any Occurrence of Amyloid-Related Imaging Abnormalities (ARIA)
Timeframe: Baseline Up to Week 24, 52
Frequency and Severity of Infusion-Related Reactions
Timeframe: Through Week 52
Secondary (2)
Change from Baseline in Mini Mental State Examination (MMSE) Score
Change from Baseline in Plasma Phosphorylated Tau217 (P-tau217)
Arms and interventions
DonanemabExperimental
Donanemab administered intravenously (IV)
Drugs: Donanemab
Sites
12 sites in 1 country